Down 34% Last Month, Should You Buy BioNTech Stock For Near-Term Gains?

Down 34% Last Month, Should You Buy BioNTech Stock For Near-Term Gains?

BioNTech , a leader in messenger RNA technology and Pfizer’s Covid-19 vaccine partner, saw its stock price decline by almost 34% over the last month, considerably underperforming the S&P 500 which remained roughly flat over the same period. There have been a couple of recent developments that hurt..